Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Advertisement
Articles by Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
RSV Vaccination Effective in Older Adults, but Protection Declines Over Time
2
Older Adults Drive Hospitalizations, Costs in the US 2024-2025 Influenza Season
3
Discontinuing GLP-1s Before or Early in Pregnancy Tied to Weight Gain, Pregnancy Complications
4
Tapinarof Shows Strong Efficacy, Sleep Benefits in Pediatric AD Across Comorbidities: Druhan Howell, MD
5
